tbuckley/cabot-search huggingface dataset:
Abstract 3671: The role of FOXQ1 in benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells.
Authors: Anuradha Sehrawat, Su-Hyeong Kim, Andreas Vogt, Shivendra V. Singh
Journal: Cancer Research (2013)

Abstract We have shown previously that breast cancer chemoprevention by benzyl isothiocyanate (BITC) in mouse mammary tumor virus-neu transgenic mice is associated with induction of E-cadherin protein expression. Loss of E-cadherin expression concomitant with induction of mesenchymal markers (eg, vimentin and fibronectin) is a biochemical hallmark of epithelial-to-mesenchymal transition (EMT). EMT is a developmental process but implicated in progression of cancer to aggressive state. We have also shown previously that BITC treatment inhibits EMT in cultured MDA-MB-231 human breast cancer cells. The present study extends these observations and investigates the mechanism by which BITC inhibits EMT. Initially, we designed experiments using another triple-negative human breast cancer cell line (SUM159) to determine generality of the BITC-mediated inhibition of EMT. Exposure of SUM159 cells to pharmacologically-relevant concentrations of BITC (2.5 and 5 μM) resulted in induction of E-cadherin protein expression, which was accompanied by suppression of vimentin protein level especially at the 5 μM dose. Protein levels of slug and snail, which are transcriptional repressors of E-cadherin, were also decreased markedly after treatment of SUM159 cells with BITC, but this effect was relatively more pronounced on slug protein level compared with snail. Similar to MDA-MB-231 cells, the BITC-mediated induction of E-cadherin protein expression in SUM159 cells was accompanied by its transcriptional upregulation as revealed by E-cadherin luciferase reporter assay. Immunofluorescence microscopy confirmed induction of E-cadherin protein and suppression of vimentin protein expression in BITC-treated SUM159 cells. BITC treatment resulted in downregulation of Forkhead Box Q1 transcription factor (FOXQ1) protein and FOXQ1 mRNA in MDA-MB-231, SUM159, and MDA-MB-468 cells. The BITC-mediated inhibition of MDA-MB-231 xenograft growth in vivo was associated with suppression of FOXQ1 protein level. Ectopic expression of FOXQ1 in a mammary epithelial cell line conferred marked protection against BITC-mediated inhibition of EMT as well as cell migration. In conclusion, the present study implicates FOXQ1 suppression in BITC-mediated inhibition of EMT in human breast cancer cells. This study was supported by the grant CA129347-06 awarded by the National Cancer Institute. Citation Format: Anuradha Sehrawat, Su-Hyeong Kim, Andreas Vogt, Shivendra V. Singh. The role of FOXQ1 in benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3671. doi:10.1158/1538-7445.AM2013-3671
Abstract 1321: Estrogen-like effects of cadmium in male mice and the involvement of MAPKs pathway
Authors: Imran Ali, Pauliina E. Penttinen-Damdimopoulou, Sari I. Mäkelä, Marika Berglund, Ulla Stenius, Annika Adamsson, Agneta Åkesson, Helen Håkansson, Krister Halldin
Journal: Cancer Research (2011)

Abstract Cadmium is a ubiquitous toxicant of environmental concern, classified as a category 1 human carcinogen. Clear estrogen-like effects of cadmium have been reported in ovariectomized rats after a single dose. Recent epidemiological findings might suggest increased risk of hormone-related cancers such as cancer of the endometrium and breast. However, the specific molecular mechanism of action is unknown. Recently, we have shown that estrogen-like effects of cadmium in female mice do not appear to be mediated via the classical estrogen receptor transcriptional pathway. However, some estrogen like effects, possibly mediated via the non-classical estrogen signaling pathway were observed. The aim of the present study was to investigate the estrogen-like effects of cadmium in male mice. ERE-luc male mice were injected subcutaneously with CdCl2 at 0.5, 5, 50 or 500 µg/kg b.w. or with 17α-ethinylestradiol (EE2) on three consecutive days. Testicular weights and histology, body and organ weight, Cd-tissue retention, activation of MAPK pathways and ERE dependent luciferase expression were investigated. Body weight and relative liver and kidney weights were not altered in any of the CdCl2 or EE2 treated animals as compared to the control. Relative testis weights were significantly decreased in 0.5 and 50µg CdCl2/kg b.w. treated animals as compared to control. Testicular histology analysis showed no significant changes in the tubulus diameter and epithelial thickness at stage VII, however some apoptotic cells were observed in mice treated with CdCl2. No significant alterations in ERE mediated luciferase activity were detected in any of the CdCl2 treated groups. Phosphorylation of Mdm2 was significantly increased at relatively low-dose of CdCl2 (5µg/kg b.w.), whereas no significant changes in phosphorylation of Akt were observed in CdCl2 or EE2 treated animals. Phosphorylation of Erk was found to be significantly increased after exposure to 0.5, 5 and 50µg of CdCl2/kg b.w. as compared to control. Gene expression of c-myc, c-fos, c-jun and p53 appeared to be decreased at relatively low dose of CdCl2 (5µg/kg b.w). No significant changes were observed in the expression of HSP32, p38, SP1 or ER-alpha after CdCl2 exposure. In conclusion the results suggest the involvement of MAPKs signaling pathways in cadmium induced effects in vivo after short term exposure at the doses investigated. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1321. doi:10.1158/1538-7445.AM2011-1321
Excessive Hypertension of Long Duration
Authors: Alex. M. Burgess
Journal: New England Journal of Medicine (1948)

IN THE Journal of the American Medical Association of December 21, 1932, under the heading, "Queries and Minor Notes," appears the following question:Can you give me any statistics or other definite information of assistance in the prognosis of blood pressure? For example, how definitely can one say how long a person with a pressure of 200 systolic will survive, or one with 250, or one with a diastolic of 100 or 120? I realize that many factors enter in, but I am especially interested in the effect such high pressures have on individuals who show no cardiac or renal . . .
INITIATION OF LOOP DIURETICS HAS NO ASSOCIATION WITH 30-DAY ALL-CAUSE OR HEART FAILURE READMISSIONS OR ALL-CAUSE MORTALITY IN OLDER MEDICARE BENEFICIARIES HOSPITALIZED FOR HEART FAILURE
Authors: Taimoor Hashim, Charity Morgan, Sijian Zhang, Sumanth Prabhu, Prakash Deedwania, Ross Fletcher, Gregg Fonarow, Javed Butler, Wilbert Aronow, Wen-Chih H. Wu, Chris Adamopoulos, Ioannis Kanonidis, Stefan D. Anker, Richard M. Allman, Ali Ahmed
Journal: Journal of the American College of Cardiology (2016)
Abiotrophia Species Bacteremia and a Mycotic Aneurysm in an Intravenous Drug Abuser
Authors: Michael K. Leonard, Christian P. Pox, David S. Stephens
Journal: New England Journal of Medicine (2001)

The New Eng land Jour nal of Medicine pertrophy, and an aortic-valve area of less than 0.6 cm 2 or an aortic-valve index no higher than 0.6 cm 2 per square meter of body-surface area). 2 However, none of these echocardiographic findings have demonstrated the predictive power that Rosenhek et al. report for the degree of valvular calcification and the increase in aortic-jet velocity.Their results add to the existing evidence that an absence of symptoms is an insufficient reason to delay aortic-valve replacement in certain cases.The findings also shed light on the matter of which patients should be considered for early surgery.
Intratumoral CCL21 and checkpoint blockade cooperatively inhibit NSCLC tumor growth in vivo to a greater extent than either monotherapy alone
Authors: Ramin Salehi-rad, Tonya C. Walser, Natalie Yakobian, Stacy J. Park, Mi-Heon Lee, Jay Moon Lee, Sherven Sharma, Steven M. Dubinett
Journal: Journal of Thoracic Oncology (2016)
Prepregnancy Weight and the Risk of Adverse Pregnancy Outcomes
Authors: Sven Cnattingius, Reinhold Bergström, Loren Lipworth, Michael S. Kramer
Journal: New England Journal of Medicine (1998)

Obesity before pregnancy is associated with an increased risk of several adverse outcomes of pregnancy. The risk profiles among lean, normal, or mildly overweight women are not, however, well established.
ECHOCARDIOGRAPHIC ASSESSMENT OF CHANGES IN RV FUNCTION IN PATIENTS WITH MITRAL REGURGITATION UNDERGOING MITRACLIP PLACEMENT
Authors: Rebecca L. Baumann, Dee Dee Wang, Kristen Brooks, Rishi Panchal, Timothy Raymond, Taylor Andrew, Sachin Parikh, Bryan Zweig, John Schairer, Marvin Eng, Hassan Nemeh, Karthikeyan Ananthasubramaniam, Adam Greenbaum
Journal: Journal of the American College of Cardiology (2016)
HOMOZYGOSITY FOR HLA-C2 ALLELES IS NEGATIVELY ASSOCIATED WITH TREATMENT RESPONSE WITH PEGLYATED INTERFERON-γ AND RIBAVIRIN IN HEPATITIS C GENOTYPE 1 INFECTED INDIVIDUALS
Authors: M Collison, J L Chin, A Abu Shanab, R MacNicholas, J Connell, M Carr, W Hall, P A McCormick
Journal: Gut (2013)

<h3>Introduction</h3> Standard therapy for chronic hepatitis C virus (HCV) infection consists of pegylated interferon-? and ribavirin. This treatment is only effective in 40-50% of patients with HCV genotype 1 (G1) infections. The IL28B single nucleotide polymorphism (SNP) is well described but other host genetic factors may influence treatment response. <h3>Aims/Background</h3> This study investigated associations between host genetic variation and treatment response to standard therapy in HCV genotype 1 and 3 (G3) infected patients. The genetic markers investigated comprised four IL28B SNPs (G1 n=89; G3 n=82): rs12979860, rs8099917, rs4803221, rs7248668; and HLA-C alleles (G1 n=71; G3 n=67): C1/C1, C1/C2 or C2/C2. <h3>Method</h3> Nucleic acids were extracted from serum and plasma and SNP typing was performed by allelic discrimination real-time PCR, PCR-SSP and sequencing approaches. <h3>Results</h3> For HCV genotype 1 infections, the IL28B SNP rs12979860 was the most significant genetic marker for predicting non-response to treatment, with a positive predictive value of 81.3% in patients homozygous for the T allele. HLA-C2 homozygosity was found to be significantly associated with non-response in genotype 1 infections (p=0.023). 19% (7/37) of non-responders were HLA-C2/C2 homozygoytes compared to no patients (0/34) with this genotype who achieved SVR. All HCV genotype 1 patients homozygous for HLA-C2, who did not achieve SVR, were rs12979860 heterozygotes (C/T). For HCV genotype 3 patients, no significant association was observed between HLA-C and non-response to treatment (p=0.09). Prediction measures were calculated using non-response as the outcome of interest, and each genetic variant as the “test” for non-response. The * notation refers to all genotypes containing that allele. <h3>Conclusion</h3> A combination of IL28B rs12979860 and HLA-C host genotype may better predict treatment outcomes to standard therapy for HCV genotype 1 infections.
A 15-YEAR WARRANTY PERIOD FOR ASYMPTOMATIC INDIVIDUALS WITHOUT CORONARY ARTERY CALCIUM: A PROSPECTIVE FOLLOW-UP OF 9,715 INDIVIDUALS
Authors: Valentina Valenti, Bríain ó Hartaigh, Heidi Gransar, Iksung Cho, Joshua Schulman-Marcus, Ran Heo, Tracy Callister, Leslee Shaw, Joseph Knapper, Anita Kelkar, Pratik Sandesara, Fay Lin, Quynh Truong, James Min
Journal: Journal of the American College of Cardiology (2015)
SAT0588-HPR Swimming is as Effective as Walking for Treating Fibromyalgia: a Randomized Controlled Trial.
Authors: G. Fernandes, F. Jennings, A. L. Buosi, M. Nery, J. Natour
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Background: Fibromyalgia (FM) is a chronic widespread pain syndrome that causes deterioration of physical capacity. Exercises are fundamental in the treatment of FM, however, it is not known the effects of swimming in patients with FM. <h3>Objectives</h3> Objective: To evaluate the effects of swimming on pain, functional capacity, quality of life, and aerobic capacity in patients with FM, compared to walking. <h3>Methods</h3> Methods: Seventy-five women with diagnosis of FM according to ACR criteria with age between 18 and 60 years were selected. The patients were randomized to swimming group (SG) or walking group (WG). The SG performed swimming in front-crawl style and the heart rate (HR) training was defined by subtracting 10 beats from anaerobic threshold heart rate to compensate underwater horizontal position. The WG performed walking at anaerobic threshold HR. Exercise sessions had duration of 50 minutes and were performed three times a week for 12 weeks. The outcome measures were visual analogue scale (VAS) for pain, Time Up and Go Test (TUG) for functional capacity, Fibromyalgia Impact Questionnaire (FIQ) for health-related quality of life and SF 36 for general quality of life. Aerobic capacity was measured by an incremental cardiopulmonary exercise testing protocol by treadmill. The evaluations were done by a blinded assessor at baseline (T0), 6 (T6) and 12 weeks (T12) after randomization. <h3>Results</h3> Results: Thirty-nine patients were randomized to SG and 36 to WG. The groups were homogeneous at baseline regarding clinical and demographic characteristics. After 12 weeks, both groups improved pain, functional capacity and quality of life (FIQ and SF 36) compared to baseline, however there were no differences between groups. Regarding aerobic capacity, both groups did not show changes over time. Tolerance to exercise, measured by adherence to programs, was similar in both groups (77.8% in SG and 72.2% in WG). <h3>Conclusions</h3> Conclusions: Swimming is as effective as walking in improving pain, functional capacity, health-related quality of life and general quality of life in patients with FM. In addition, swimming is well-tolerated by patients with FM. However, clinical improvements are not associated to aerobic capacity. <h3>References</h3> Altan L, Bingöl U, Aykaç M, et al. Investigation of the effects of pool-based exercise on fibromyalgia syndrome. Rheumatol Int, 2004; 24: 272–277. Häuser W, Klose P, Langhorst J, Moradi B, Steinbach M, Schiltenwolf M, Busch A: Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomized controlled trials. Arthritis Res Ther 2010, 12: R79. <h3>Disclosure of Interest</h3> G. Fernandes: None Declared, F. Jennings: None Declared, A. L. Buosi: None Declared, M. Nery: None Declared, J. Natour Grant/research support from: FAPESP- Fundação de Apoio a Pesquisa de São Paulo
DESIRE RISK SCORE FOR PREDICTION OF IN-HOSPITAL AND LATE FOLLOW-UP MACE AFTER PERCUTANEOUS CORONARY INTERVENTIONS WITH DRUG-ELUTING STENTS
Authors: Jose de Ribamar Costa, Adriana Moreira, Amanda Sousa, Ricardo Costa, Dimytri Siqueira, Galo Maldonado, Manuel Cano, Ricardo Pavanello, Lucas Damiani, Cantídio Campos Neto, J. Sousa
Journal: Journal of the American College of Cardiology (2016)
PTH-058 Trainee Colonoscopists Acquire Competency at Different Rates, as Determined by Cusum Analysis Of Colonoscopy Data From The Jets Database
Authors: S T Ward, M A Mohammed, T Ismail, R Valori, P Dunckley
Journal: Gut (2013)

<h3>Introduction</h3> The number of colonoscopies required to reach competency is not well established. Nevertheless, a minimal number forms part of UK certification criteria. The Cusum technique is a statistical analysis of sequential data to determine if a process is ‘in control’. The Joint Advisory Group on GI Endoscopy have developed an e-portfolio for users to record their endoscopic experience. The primary aim of this study was to determine the range of experience required by individuals to attain a caecal intubation rate (CIR) ≥90%, as defined by Cusum. A secondary aim was to assess which training factors are associated with attaining competence. <h3>Methods</h3> Inclusion criteria were all e-portfolio users who had performed ≤50 (‘baseline’) colonoscopies prior to submission of data to the e-portfolio; termed ‘trainees’. All colonoscopy records for the trainees were retrieved from the e-portfolio database and learning curve-Cusum analysis was performed. This analysis of colonoscopy completion reports the number of procedures required for CIR performance to reach ≥90%. A colonoscopy was defined complete if the caecum or ileum was reached and was performed without assistance. Trainees who had attained a CIR≥90% were compared to those with a CIR &lt; 90% for differences in previous endoscopic experience, case volume and other trainee factors by univariate (Mann-Whitney, Chi-squared) and multivariate (binomial logistic regression) analysis. <h3>Results</h3> The e-portfolio contained 169,515 colonoscopy records entered by 1,572 different users. 265 users (‘trainees’) were confirmed to have performed ≤50 baseline colonoscopies and were included in subsequent analyses. By Cusum method, 39 trainees attained a CIR≥90%; 226 achieved a CIR &lt; 90%. For those trainees with over 250 procedures, only 47% attained a CIR≥90%. Factors associated with attaining CIR≥90% were high number of procedures (P &lt; 0.01), high number of colonoscopies per month (P &lt; 0.01), and prior experience of more than 100 sigmoidoscopies (P = 0.017) by univariate and multivariate analysis. Nurse endoscopists attained competency at a higher rate than gastroenterology or surgical trainees by univariate (P = 0.01) but not multivariate analysis. <h3>Conclusion</h3> This is the largest study to date by both procedure and trainee numbers assessing colonoscopy competency by Cusum method. Trainees achieve competency at different rates. A high proportion of trainees will not attain a CIR &gt; 90% even after 250 procedures. High case volume and prior sigmoidoscopy experience are associated with a CIR &gt; 90%. The potential of both these factors to influence the attainment of competency should be exploited within endoscopy training programmes. <h3>Disclosure of Interest</h3> None Declared.
Dietary Habits and Prognostic Factors in Breast Cancer
Authors: L E Holm, E Callmer, M L Hjalmar, E Lidbrink, B Nilsson, L Skoog
Journal: JNCI Journal of the National Cancer Institute (1989)

The relationship between dietary habits and prognostic factors for breast cancer was studied in 240 women aged 50-65 years who had surgery for breast cancer between 1983 and 1986. A dietary history interview was conducted within the 4 months following resection of the primary tumor. In the stepwise multivariate analysis, the multiple-odds ratio (OR) for having a tumor greater than or equal to 20 mm in diameter was 0.95 (95% confidence interval, 0.91-0.99) for each 1-g increase in fiber intake per 10 MJ of energy intake. Compared with patients having tumors poor in estrogen receptor (ER), those having ER-rich tumors (greater than or equal to 0.10 fmol/microgram of DNA) were older (P less than .01) and reported carbohydrate intake yielding higher E% (percentage of total energy intake) (P less than .01) and higher retinol intake per 10 MJ (P less than .05). The OR for having an ER-rich tumor was 1.58 (95% confidence interval, 1.08-2.31) for each 1-mg increase in retinol intake per 10 MJ; 1.09 (95% confidence interval, 1.02-1.16) for each additional year of age; and 1.08 (95% confidence interval, 1.02-1.13) for each 1% increment in E% from carbohydrates. These results suggest that the dietary patterns of the western world (e.g., high fat intake and low intake of carbohydrates and fiber) affect certain prognostic factors in breast cancer, such as tumor size and ER content of the tumor.
Abstract LB-402: New fusion genes in lung adenocarcinoma revealed from next generation RNA-seq
Authors: Young Seok Ju, Won-Chul Lee, Jong-Yeon Shin, Jong-Il Kim, Jin-Hyoung Kang, Young Tae Kim, Jeong-Sun Seo
Journal: Cancer Research (2012)

Abstract Cancer is a genomic disease. A subset of somatic driver mutations has been reported in lung adenocarcinoma in the past few years, such as somatic mutations in EGFR, KRAS and EML4-ALK fusion gene. Identification of driver mutations in lung cancer is very important, since several anti-cancer drugs targeting them (gefitinib, erlotinib, and crizotinib) have shown dramatic clinical outcomes for the treatment of lung adenocarcinomas. However, a large proportion of lung cancer patients have been observed to have none of them in their cancer genome. More than 40% of lung adenocarcinoma patients appear to be driven by unknown genetic events. Gene fusions represent a subset of genetic alteration in human cancer. We recently identified a fusion gene joining KIF5B and RET transforming tyrosine kinase in tumor tissues of lung adenocarcinoma patients as a driver mutation using integration of whole-genome and transcriptome sequencing of cancer tissue [1]. We expanded our study by sequencing more transcriptomes of lung adenocarcinomas with paired normal tissues. Overall, we obtained transcriptome sequences from 88 primary lung adenocarcinomas, 53.5% (n=47) of them were negative for EGFR, KRAS and EML4-ALK. Our approach identified many novel fusion events in lung adenocarcinoma, such as CD74-ROS1, SLC34A2-ROS1, and additional fusions of cancer related genes. Majority of these fusion genes and known somatic mutations were mutually exclusive (p=0.001), suggesting these fusion genes are highly likely to be the driver mutations of lung adenocarcinoma. Overall, fusion genes account for ∼15% of genetic causes of lung adenocarcinoma according to our dataset. We will discuss those fusion genes and frequent somatic mutations of lung adenocarcinoma revealed from transcriptome sequencing of 88 lung adenocarcinomas. REFERENCE 1. Fusion of KIF5B and RET transforming gene in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Research (2012), Advance online publication Dec 22 2011. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-402. doi:1538-7445.AM2012-LB-402
Pulmonary Venous Stenosis on Ventilation-Perfusion Scintigraphy
Authors: Jorge Daniel Oldan, Igor Klem, Salvador Borges-Neto
Journal: Clinical Nuclear Medicine (2014)

A case of pulmonary vein stenosis as a result of prior atrial fibrillation focus procedures for atrial fibrillation, correlated with magnetic resonance (MR) pulmonary angiography, is presented. Restricted flow to the right lung in similar quantities measured by nuclear medicine and MR techniques is observed, with perfusion scintigraphy demonstrating decreased but not absent flow to the right lung and left lower lobe and with MRI demonstrating restriction of flow through the right and left lower pulmonary veins. The sharp differences in venous outflow can be seen by MR, whereas their effects are visible by scintigraphy.